Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset-Reference-Cited by-同舟云学术

Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset

Published:2023 Issue:3 Volume:10 Page:94
ISSN:2311-3006
Container-title:Journal of Cancer Research and Practice
language:en
Short-container-title:J Cancer Res Pract

Author:

Huang Chiun-Sheng,Chang Yuan-Ching,Rau Kun-Ming,Chen Dar-Ren,Chao Tsu-Yi,Hou Ming-Feng

Publisher

Medknow

Subject

General Medicine

Reference32 articles.

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory. In: Cancer Tomorrow. Lyons, France: International Agency for Research on Cancer; 2020. Available from: https://gco.iarc.fr/tomorrow.[Last accessed on 2020 Jun 12].

2. Extending survival with chemotherapy in metastatic breast cancer;O'Shaughnessy;Oncologist,2005

3. Estrogen receptors and cell proliferation in breast cancer;Ciocca;Trends Endocrinol Metab,1997

4. Treatment of estrogen receptor-positive breast cancer;Lumachi;Curr Med Chem,2013

5. Mechanisms of endocrine resistance in breast cancer;Osborne;Annu Rev Med,2011

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Corrigendum: Safety and Efficacy of Everolimus Plus Exemestane in Postmenopausal Women with Treatment-refractory Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Analysis from EVEREXES Taiwan Subset;Journal of Cancer Research and Practice;2024-04